

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2  
 APPLICATION NO. : 10/684229  
 DATED : July 4, 2006  
 INVENTOR(S) : Lin Zhi et al.

Page 1 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**IN THE TITLE PAGES:**

In Item [56] References Cited, in U.S. PATENT DOCUMENTS:

please add the following reference: --6,001,846 A 12/1999 Edwards et al. 514/285--  
 in 6,566,358 please replace "Zhi et al." with --Zhang et al.--  
 in 6,566,372 please replace "West et al." with --Zhi et al.--

In Item [56] References Cited, in OTHER PUBLICATIONS:


in Hamann et al., please replace "dihyrdo" with --dihydro--

At column 8, Table A, row R<sup>1</sup>, please replace "C<sub>1</sub>-C haloalkyl" with --C<sub>1</sub>-C<sub>4</sub> haloalkyl--  
 at column 9, Table A, row R<sup>9</sup>, please replace "CONR<sup>H</sup>R<sup>12</sup>" with --CONR<sup>11</sup>R<sup>12</sup>--  
 at column 11, Table A, below row R<sup>16</sup>, please replace "R<sup>15</sup>" with --R<sup>16</sup>--

Please replace Claims 12, 13, 14, and 15 with the following Claims:

Col. 40

12. A compound of the formula:



(I)

wherein:

- R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, ~~CONR<sup>11</sup>R<sup>12</sup>~~, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;
- R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> haloalkyl; or
- R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;
- R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> heteroalkyl; or
- R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or
- R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;

CONR<sup>11</sup>

Note

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.


Page 2 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

$R^8$  through  $R^{10}$  each independently is selected from the group of hydrogen, F, Cl, Br, I,  $\text{NO}_2$ , CN,  $\text{OR}^{11}$ ,  $\text{NR}^{11}\text{R}^{12}$ ,  $\text{SR}^{11}$ ,  $\text{COR}^{11}$ ,  $\text{CO}_2\text{R}^{11}$ ,  $\text{CONR}^{11}\text{R}^{12}$ ,  $\text{C}_1\text{--C}_8$  alkyl,  $\text{C}_1\text{--C}_8$  heteroalkyl,  $\text{C}_1\text{--C}_8$  haloalkyl, allyl,  $\text{C}_2\text{--C}_8$  alkenyl and  $\text{C}_2\text{--C}_8$  alkynyl;  
 $R^{11}$  and  $R^{12}$  each is independently selected from the group of hydrogen,  $\text{C}_1\text{--C}_4$  alkyl,  $\text{C}_1\text{--C}_4$  heteroalkyl, and  $\text{C}_1\text{--C}_4$  haloalkyl;  
 $R^{13}$  is hydrogen;  
 $R^{14}$  and  $R^{16}$  taken together form a bond or “—O—” bridge;  
 $R^{15}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  each independently is selected from the group of hydrogen, F, Cl,  $\text{C}_1\text{--C}_4$  alkyl, and  $\text{C}_1\text{--C}_4$  haloalkyl;  
 $R^{21}$  is hydrogen; and  
 $n$  is 0, 1, 2, or 3;  
or a pharmaceutically acceptable salt thereof.

Col. 41

13. A compound of the formula:



(I)

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 3 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R<sup>1</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>R<sup>11</sup>, and CONR<sup>11</sup>R<sup>12</sup>;  
R<sup>2</sup> and R<sup>3</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> haloalkyl; or  
R<sup>2</sup> and R<sup>3</sup> taken together form a cycloalkyl ring of from three to twelve carbons;  
R<sup>4</sup> through R<sup>7</sup> each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> heteroalkyl; or  
R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or  
R<sup>6</sup> and R<sup>7</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;  
R<sup>8</sup> through R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, CN, OR<sup>11</sup>, NR<sup>11</sup>R<sup>12</sup>, SR<sup>11</sup>, COR<sup>11</sup>, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, allyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl;  
R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>13</sup> is hydrogen;  
R<sup>14</sup>, R<sup>15</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>16</sup> and R<sup>17</sup> taken together are selected from the group of methyldene, mono-substituted methyldene, and di-substituted methyldene;  
R<sup>21</sup> is hydrogen; or  
R<sup>21</sup> and R<sup>20</sup> taken together form a bond;  
n is 0, 1, 2, or 3;  
or a pharmaceutically acceptable salt thereof.

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION


PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 4 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 42

14. A compound of the formula:



(I)

wherein:

- $R^1$  is selected from the group of hydrogen,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  heteroalkyl,  $COR^{11}$ ,  $CO_2R^{11}$ ,  $SO_2R^{11}$ , and  $CONR^{11}R^{12}$ ;  
 $R^2$  and  $R^3$  each independently is selected from the group of hydrogen,  $C_1-C_6$  alkyl, and  $C_1-C_6$  haloalkyl; or  
 $R^2$  and  $R^3$  taken together form a cycloalkyl ring of from three to twelve carbons;  
 $R^4$  through  $R^7$  each independently is selected from the group of hydrogen, F, Cl, Br, CN,  $OR^{11}$ ,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, and  $C_1-C_4$  heteroalkyl; or  
 $R^5$  and  $R^7$  taken together form a bond; or  
 $R^6$  and  $R^7$  taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;  
 $R^8$  through  $R^{10}$  each independently is selected from the group of hydrogen, F, Cl, Br, I,  $NO_2$ , CN,  $OR^{11}$ ,  $NR^{11}R^{12}$ ,  $SR^{11}$ ,  $COR^{11}$ ,  $CO_2R^{11}$ ,  $CONR^{11}R^{12}$ ,  $C_1-C_8$  alkyl,  $C_1-C_8$  heteroalkyl,  $C_1-C_8$  haloalkyl, allyl,  $C_2-C_8$  alkenyl and  $C_2-C_8$  alkynyl;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684,229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 5 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>11</sup> and R<sup>12</sup> each is independently selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>13</sup> is hydrogen;  
R<sup>14</sup>, R<sup>15</sup>, R<sup>17</sup>, R<sup>20</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkyl;  
R<sup>16</sup> and R<sup>18</sup> taken together form a bond when n is 1;  
R<sup>16</sup> and R<sup>19</sup> taken together form a bond when n is 0;  
R<sup>21</sup> is hydrogen; and  
n is 0, 1, 2, or 3;  
or a pharmaceutically acceptable salt thereof.

Col. 42-45

15. A Compound selected from the group of:

(±)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);  
(±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);  
(+)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);  
(-)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);  
(±)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 6 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);
- (±)-(51,1'1)-5-3-methyl-2-cyclohexenyl)-9,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 7 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);
- (±)-(51,1'u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);
- (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);
- (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);
- (±)-(51,1'u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);
- (±)-(51,1'1)-5-(3-ethylidenecyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 8 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);
- (±)-(51,1'1)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);
- (±)-(51,1'u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);
- (±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);
- (±)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71);
- (+)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);
- (-)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);
- (±)-(51,1'u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);
- (±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);



UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 9 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'l)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);  
(±)-(51,1'u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);  
(±)-(51,1'l)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);  
(±)-(51,1'u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);  
(±)-(51,1'l)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);  
(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 84);  
(±)-(51,1'l)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-~~difluoro~~<sup>difluoro</sup>-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85); <sup>cyclohexyl</sup>  
(±)-5-(3-methylidene-~~cyclohexyl~~<sup>cyclohexyl</sup>)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87);  
(±)-(51,1'u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);  
(±)-(51,1'l)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);  
(±)-(51,1'l)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);  
(±)-(51,1'u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);

Note  
Note

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,071,205 B2  
APPLICATION NO. : 10/684229  
DATED : July 4, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 10 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);  
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);  
(±)-(51,1'1)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);  
(±)-(51,1'u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and  
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

Note

This certificate supersedes certificate of correction  
issued November 28, 2006.

~~Signed and Sealed this~~

~~Twenty-eighth Day of November, 2006~~

~~Witness my hand and the Great Seal of the United States this~~